Literature DB >> 34341015

Ipilimumab Combination Dosing: Less is More.

Max Jameson-Lee1, Jason J Luke1.   

Abstract

Ipilimumab with and without anti-Programmed Death 1 (PD-1) improved overall survival (OS) in melanoma. Despite this, the optimal dose and therapeutic mechanism of ipilimumab in patients remains unclear. KEYNOTE-029 and other studies suggest that low-dose ipilimumab with anti-PD1 maintains efficacy while decreasing toxicity, emphasizing T-cell trafficking and reinvigoration as likely mechanisms. See related article by Long et al., p. 5280. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34341015      PMCID： PMC8807780          DOI： 10.1158/1078-0432.CCR-21-2406

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.

Authors:  Anu Sharma; Sumit K Subudhi; Jorge Blando; Jorge Scutti; Luis Vence; Jennifer Wargo; James P Allison; Antoni Ribas; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2018-07-27       Impact factor: 12.531

Review 2.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

Review 3.  Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.

Authors:  Christopher S Garris; Jason J Luke
Journal:  Clin Cancer Res       Date:  2020-04-24       Impact factor: 12.531

4.  Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.

Authors:  Daniel J Olson; Zeynep Eroglu; Bruce Brockstein; Andrew S Poklepovic; Madhuri Bajaj; Sunil Babu; Sigrun Hallmeyer; Mario Velasco; Jose Lutzky; Emily Higgs; Riyue Bao; Timothy C Carll; Brian Labadie; Thomas Krausz; Yuanyuan Zha; Theodore Karrison; Vernon K Sondak; Thomas F Gajewski; Nikhil I Khushalani; Jason J Luke
Journal:  J Clin Oncol       Date:  2021-05-04       Impact factor: 50.717

5.  Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.

Authors:  Georgina V Long; Caroline Robert; Marcus O Butler; Felix Couture; Matteo S Carlino; Steven O'Day; Victoria Atkinson; Jonathan S Cebon; Michael P Brown; Stéphane Dalle; Andrew G Hill; Geoffrey T Gibney; Steven McCune; Alexander M Menzies; Cuizhen Niu; Nageatte Ibrahim; Blanca Homet Moreno; Adi Diab
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531
  5 in total
  1 in total

1.  The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.

Authors:  Paolo A Ascierto; Allison Betof Warner; Christian Blank; Corrado Caracò; Sandra Demaria; Jeffrey E Gershenwald; Nikhil I Khushalani; Georgina V Long; Jason J Luke; Janice M Mehnert; Caroline Robert; Piotr Rutkowski; Hussein A Tawbi; Iman Osman; Igor Puzanov
Journal:  J Transl Med       Date:  2022-05-10       Impact factor: 8.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.